Dr. Mittendorf on Nelipepimut-S Plus GM-CSF in Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.

Elizabeth A. Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses a clinical trial examining nelipepimut-S plus GM-CSF vaccine therapy as a treatment for patients with breast cancer.

This HER2-derived peptide vaccine is immunogeneic and aimed to prevent disease recurrence, explains Mittendorf. In combination with GM-CSF, the strategy is to inoculate patients who are rendered disease-free with their standard therapy. The goal is to stimulate an immune response to help prevent recurrence.

Earlier phase studies show that the vaccine strategy has decreased recurrence rates by approximately 50%. This could potentially lead to an FDA approval of the combination.

<<<

View more from the 33rd Annual Miami Breast Cancer Conference